



ISSN: 0975-833X

Available online at <http://www.journalcra.com>

International Journal of Current Research
Vol. 14, Issue, 10, pp.22559-22560, October, 2022
DOI: <https://doi.org/10.24941/ijcr.44196.10.2022>

INTERNATIONAL JOURNAL
OF CURRENT RESEARCH

RESEARCH ARTICLE

URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI –ANTIBIOGRAM OF NITROFURANTOIN VERSUS CIPROFLOXACIN AT A TERTIARY CARE TEACHING HOSPITAL, TIRUPATI

^{1,*}Dr. Pralitha Madhuri, G., ²Dr. Rajaram, G. ³Dr. Srinivasa Rao, C.H.

¹Post graduate, Department of Microbiology, S.V. Medicalcollege,Tirupati

²Associate Professor, Department of Microbiology, S.V. Medical College ,Tirupati

³Associate Professor, Department of Microbiology, S.V. Medical College, Tirupati

ARTICLE INFO

Article History:

Received 20th July, 2022
Received in revised form
17th August, 2022
Accepted 19th September, 2022
Published online 30th October, 2022

Key words:

Ayurveda, Aragwadhadi Kashayam,
Dermatitis, Lumpy Skin Disease virus,
LSD.

*Corresponding Author:
Dr. Pralitha Madhuri, G.,

ABSTRACT

Objective: Urinary tract infection is one of the most common bacterial infection. Escherichia coli is one of the commonest organism causing Urinary tract infection .Ciprofloxacin (fluoroquinolones) are the most commonly used as first line agents for treatment of urinary tract infections caused by Escherichia coli. Inappropriately excessive use of Ciprofloxacin (fluoroquinolones) has detrimental impact . Present study is antibiogram between Nitrofurantoin Versus Ciprofloxacin as first line agents for treatment of Urinary tract infection caused by Escherichia coli. **Method:** A total of 1205 urine samples collected between MAY2019 to October 2019 for culture and pathogens identified by conventional methods. Antibiotic susceptibility pattern determined by Kirby-Bauer disc diffusion method. **Result:** Among 1205 urine samples 203 samples shown culture positive, in this 39 samples shown Escherichia coli. Among them 28(71.7%) shown resistance to Ciprofloxacin and about 6 (15.3%) shown resistance to Nitrofurantoin. **Conclusion:** This study concludes that Nitrofurantoin is a good Ciprofloxacin sparing drug. .It is suggested that Nitrofurantoin might be the first choice for treatment of urinary tract infection caused by Escherichia coli ,needs further studies regarding its side effects

Copyright©2022, Pralitha Madhuri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Pralitha Madhuri, G., Dr. Rajaram, G. Dr. Srinivasa Rao, C.H. 2022. "Urinary tract infections caused by escherichia coli –antibiogram of nitrofurantoin versus ciprofloxacin at a tertiary care teaching hospital, Tirupati". *International Journal of Current Research*, 14, (10), 22559-22560.

INTRODUCTION

Urinary tract infection is one of the most common bacterial infection both in community and hospital settings. Escherichia coli is one of the commonest organism causing urinary tract infection. E coli was the causative pathogen in 70-95% of uncomplicated UTIs, Empirical treatment for UTI is often prescribed without urine culture or before urine culture results are available, according to treatment guidelines empirical treatment choices should be based on local or regional susceptibility data. Escherichia coli harbor genes conferring resistance to all antibiotics and also plasmids harboring resistance determinants ,such that acquisition of resistance to new antibiotics may only be a matter of time . so appropriate antibiotic should be prescribed to treat UTI. Ciprofloxacin (Fluoroquinolones) is the most commonly used as first line agents for treatment of UTI. Inappropriately excessive use of Ciprofloxacin has detrimental impact. Present study is comparison of antibiogram between Nitrofurantoin versus Ciprofloxacin as first line agents for treatment of Urinary tract infection.

AIM AND OBJECTIVES: This study was undertaken to compare antibiogram between Nitrofurantoin versus Ciprofloxacin as first line agents for treatment of UTI caused by Escherichia coli.

MATERIALS AND METHODS



Urine samples received from in patients and out patients from May 2019 to October 2019 were included in the study.

SAMPLE COLLECTION METHODS: Freshly voided midstream urine specimens were collected under strict aseptic precautions in a suitable sterile wide mouthed container. Samples were transported immediately to the laboratory for Culture and identification .Each urine sample was inoculated on MacConkey agar and blood agar. The culture plates were incubated at 37c for 24 hours and observed for growth colonies.

The plates showing significant growth as per Kass count were processed for further identification. Escherichia coli isolated was identified by conventional biochemical reactions. The antibiotic susceptibility testing was performed using Kirby-Bauer's disc diffusion technique as described by Clinical and Laboratory Standards Institute guidelines.

RESULTS

Out of the 1205 urine samples received from patients having clinically suspected urinary tract infections attending SVMC Tirupati subjected to culture. 203(17.2%) showed significant growth, 871(72.2%) were negative for culture, 101(8.4%) showed contamination and 30(2.4%) showed insignificant growth. Among 203 samples with significant growth 39 samples were shown *Escherichia coli*. Among them 28 samples (71.7%) shown resistance to Ciprofloxacin only 11 samples are sensitive to it. Where as about 6 samples(15.3%) shown resistance to Nitrofurantoin and 33 samples are sensitive to Nitrofurantoin



DISCUSSION

Although antibiotics shorten the duration of symptoms and cure >90% of UTIs, it is critical to choose the appropriate antibiotic. Due to the increasing use of antibiotics, urinary pathogens have shown a slow but steady increase in resistance to several antibiotics with the increasing usage of quinolones as a primary treatment for UTI there has been increasing resistance as similar to Kothari's study, and in this study the prevalence of *Escherichia coli* resistance to ciprofloxacin increased similar to study conducted by Iqbal J and Konar J.

The lower cure rates and the increasing resistance with ciprofloxacin no longer make quinolones the first choice for treatment of UTIs. The broad range of bactericidal action of Nitrofurantoin such as inhibiting protein and cell wall synthesis, DNA, RNA synthesis, aerobic energy metabolism and relative lack of accumulated resistance to the drug over many years Nitrofurantoin might be extremely effective in treating UTIS caused by *E. coli*.

CONCLUSION

Nitrofurantoin is a good Ciprofloxacin sparing drug in the treatment of urinary tract infections caused by *Escherichia coli*, showing only 15.3% resistance compared to 71% resistance shown by Ciprofloxacin. IT is an acceptable first line agent for uncomplicated UTIs. A reconsideration of UTI treatment guidelines might now be appropriate.

Limitation: Comparative antibiogram of *Escherichia coli* causing UTI in males and females separately is not done. Comparative antibiogram study in children acquiring UTI by *Escherichia coli* is not done. No separate comparative antibiogram study for UTI caused by *Escherichia coli* in pregnant women is not done in this study.

REFERENCES

1. Cox CE. Nosocomial urinary tract infections. *Urology*. 1988Sep;32(3):210-5
2. Kalpana Gupta. MD ,MPH; Thomas. M.Houston .MD ;and Walter E Seamm, MD. Increasing Antimicrobial Resistance and the Management of Uncomplicated Community -Acquired Urinary Tract Infections *Ann Intern Med* 2001;135 41-50
3. Hooton TM. The current management strategies for community -acquired urinary tract infection. *Infect Dis Clin North Am* 2003;17: 303-32.
4. Mazzulli T. Antimicrobial resistance trends in common urinary pathogens. *Can j Urol* 2001;8(Suppl. 1): 2-5.
5. Wagenlehner F, Stower-Hoffmann J, Schneider-Brachert W, Naber KG, Lehn N. Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of *Escherichia coli* to Fluoroquinolones in urology. *Int J Antimicrob Agents* 2000;15:207-11
6. McGraw -Hill. access Medicine .Available at: <http://accessmedicine.com/popup.aspx>
